Canaccord raised the firm’s price target on ImmunoGen to $25 from $23 and keeps a Buy rating on the shares. The firm noted the company’s ELAHERE posted excellent net sales of $77.4M versu $38.7M consensus, indicating a very rapid uptake. Avastin combination use is a promising driver, which should expand. Also, PICCOLO data YE23 should pave the way for usage in platinum sensitive patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN: